All Search Results
News Releases
Apr 19, 2026, 12:00 ET Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline
More news about: Nektar Therapeutics
Apr 18, 2026, 19:35 ET Breakthrough Prize Foundation Announces Winner of the 11th Annual Breakthrough Junior Challenge
discovery, and innovation to make lives better. CSHL's DNA Learning Center (DNALC) is the largest provider of hands-on instruction in genetics and biotechnology, reaching nearly 40,000 middle and high school students through field trips, day camps, summer camps, mentored research projects, and teacher training.
More news about: Breakthrough Prize
Apr 17, 2026, 16:01 ET Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
NORTHBROOK, Ill., April 17, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
Apr 17, 2026, 15:00 ET Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
durable pathway suppression across RAS/MAPK-driven cancers.About Nested TherapeuticsNested Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for RAS/MAPK-driven disorders. The company is advancing NST-628, a fully brain-penetrant,
More news about: Nested Therapeutics Inc.
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
CAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today announced it will present two posters at the American Association for Cancer Research
More news about: CREATE Medicines, Inc.
Organizations
Resources
Case Studies
PhRMA Increases Blog Readership & Reaches Broader Audiences with Content Syndication
PhRMA, the Pharmaceutical Research and Manufacturers of America, represents leading innovative biopharmaceutical research and biotechnology companies. PhRMA is devoted to advancing public policies in the U.S. and around the world to support innovative medical research, help patients
News Trends
The Tripledemic, Disease Awareness and More Health News Trends
dinner. Luckily, she made a full recovery! Big news in healthcare acquisitions came in December when the biotechnology company Amgen